Product
PERTUZUMAB
1 clinical trial
2 indications
Indication
Breast CancerIndication
Central Nervous System MetastasesClinical trial
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-05-20